These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 17164035

  • 1. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL, Winardi W, Jeng AY, Kwan AL.
    Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Oral administration of an inhibitor of endothelin-converting enzyme attenuates cerebral vasospasm following experimental subarachnoid haemorrhage in rabbits.
    Kwan AL, Lin CL, Chang CZ, Winardi D, Yen CP, Wu SC, Lee KS, Kassell NF, Howng SL, Savage P, Jeng AY.
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():414S-417S. PubMed ID: 12193135
    [Abstract] [Full Text] [Related]

  • 4. Continuous intravenous infusion of CGS 26303, an endothelin-converting enzyme inhibitor, prevents and reverses cerebral vasospasm after experimental subarachnoid hemorrhage.
    Kwan AL, Lin CL, Chang CZ, Wu HJ, Hwong SL, Jeng AY, Lee KS.
    Neurosurgery; 2001 Aug; 49(2):422-7; discussion 427-9. PubMed ID: 11504119
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.
    Zimmermann M, Jung CS, Vatter H, Raabe A, Seifert V.
    Neurosurg Rev; 2003 May; 26(2):125-32. PubMed ID: 12962299
    [Abstract] [Full Text] [Related]

  • 7. Plasma endothelin and big endothelin concentrations and serum endothelin-converting enzyme activity following aneurysmal subarachnoid hemorrhage.
    Juvela S.
    J Neurosurg; 2002 Dec; 97(6):1287-93. PubMed ID: 12507125
    [Abstract] [Full Text] [Related]

  • 8. Attenuation of SAH-induced cerebral vasospasm by a selective ECE inhibitor.
    Kwan AL, Lin CL, Chang CZ, Wu SC, Howng SL, Jeng AY.
    Neuroreport; 2002 Feb 11; 13(2):197-9. PubMed ID: 11893909
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction.
    Matsumoto T, Ozawa Y, Taguchi K, Kobayashi T, Kamata K.
    Peptides; 2010 Feb 11; 31(2):346-53. PubMed ID: 19962413
    [Abstract] [Full Text] [Related]

  • 12. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
    Wallace EM, Moliterni JA, Moskal MA, Neubert AD, Marcopulos N, Stamford LB, Trapani AJ, Savage P, Chou M, Jeng AY.
    J Med Chem; 1998 Apr 23; 41(9):1513-23. PubMed ID: 9554884
    [Abstract] [Full Text] [Related]

  • 13. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications.
    Jeng AY, Mulder P, Kwan AL, Battistini B.
    Can J Physiol Pharmacol; 2002 May 23; 80(5):440-9. PubMed ID: 12056551
    [Abstract] [Full Text] [Related]

  • 14. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
    Battistini B, Daull P, Jeng AY.
    Cardiovasc Drug Rev; 2005 May 23; 23(4):317-30. PubMed ID: 16614731
    [Abstract] [Full Text] [Related]

  • 15. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM, Savage P, Trapani AJ, Balwierczak JL, Jeng AY.
    J Cardiovasc Pharmacol; 1998 May 23; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition.
    Porter KE, Dickinson T, London NJ.
    J Vasc Surg; 2001 Sep 23; 34(3):548-54. PubMed ID: 11533610
    [Abstract] [Full Text] [Related]

  • 18. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
    Grantham JA, Schirger JA, Wennberg PW, Sandberg S, Heublein DM, Subkowski T, Burnett JC.
    Circulation; 2000 Apr 25; 101(16):1976-81. PubMed ID: 10779465
    [Abstract] [Full Text] [Related]

  • 19. Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.
    Kuruppu S, Rajapakse NW, Smith AI.
    Pflugers Arch; 2013 Jul 25; 465(7):929-34. PubMed ID: 23328864
    [Abstract] [Full Text] [Related]

  • 20. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
    Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M.
    Hypertension; 2005 Jun 25; 45(6):1145-52. PubMed ID: 15897363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.